

**Altered serum acylcarnitine profile is associated with the status of
nonalcoholic fatty liver disease (NAFLD) and NAFLD-related
hepatocellular carcinoma**

Kenichiro Enooku, Hayato Nakagawa, Naoto Fujiwara, Mayuko Kondo, Tatsuya Minami,
Yujin Hoshida, Junji Shibahara, Ryosuke Tateishi, Kazuhiko Koike


Supplementary Figure legends

Supplementary Figure 1. Relationships between serum levels of acylcarnitine species and liver steatosis grade in patients with NAFLD.


Supplementary Figure 2. Relationships between serum levels of acylcarnitine species and lobular inflammation grade in patients with NAFLD.

Supplementary Figure 3. Relationships between serum levels of acylcarnitine species and hepatocyte ballooning grade in patients with NAFLD.

Supplementary figure 2



Supplementary figure 3



Supplementary table 1. Correlations between acylcarnitine species and estimated glomerular filtration rate

Acylcarnitine species	eGFR	
	Spearman's Rho	<i>p</i> value
Total acylcarnitine	-0.17	0.008
C0	-0.21	0.001
AC2:0	-0.16	0.01
AC3:0	-0.17	0.008
AC4:0	-0.29	< 0.001
AC5:0	-0.14	0.02
AC6:0	0.06	0.31
AC8:0	-0.16	0.01
AC10:0	-0.16	0.01
AC12:0	-0.01	0.93
AC14:1	-0.09	0.16
AC16:0	-0.04	0.51
AC18:0	-0.04	0.59
AC18:1	-0.05	0.43